Infliximab Biosimilar (Remsima (TM)) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F17%3A10338314" target="_blank" >RIV/00216208:11110/17:10338314 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00064203:_____/17:10338314 RIV/00064165:_____/17:10338314
Výsledek na webu
<a href="http://dx.doi.org/10.1159/000453343" target="_blank" >http://dx.doi.org/10.1159/000453343</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1159/000453343" target="_blank" >10.1159/000453343</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Infliximab Biosimilar (Remsima (TM)) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre
Popis výsledku v původním jazyce
Background: The evidence on the efficacy and safety of biosimilar infliximab (IFX) in patients with inflammatory bowel diseases (IBD) is sparse. Methods: Consecutive IBD patients visiting our centre were included. One cohort composed of prospectively followed patients who were switched from original to biosimilar IFX between January and March 2015. The second cohort included retrospectively assessed anti-tumor necrosis factor α-naïve patients who started therapy between January 2015 and January 2016. Disease activity was assessed using standard clinical indices, endoscopic evaluation, and laboratory parameters (blood count, C-reactive protein (CRP) and fecal calprotectin (FC)). Trough levels and anti-drug antibodies (ATIs) were also measured. Patients were evaluated 56 weeks (W56) after switch and at week 14 (W14) and week 46 (W46) in the naïve cohort. Conclusion: Switching of IBD patients from original to biosimilar IFX is effective and safe.
Název v anglickém jazyce
Infliximab Biosimilar (Remsima (TM)) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre
Popis výsledku anglicky
Background: The evidence on the efficacy and safety of biosimilar infliximab (IFX) in patients with inflammatory bowel diseases (IBD) is sparse. Methods: Consecutive IBD patients visiting our centre were included. One cohort composed of prospectively followed patients who were switched from original to biosimilar IFX between January and March 2015. The second cohort included retrospectively assessed anti-tumor necrosis factor α-naïve patients who started therapy between January 2015 and January 2016. Disease activity was assessed using standard clinical indices, endoscopic evaluation, and laboratory parameters (blood count, C-reactive protein (CRP) and fecal calprotectin (FC)). Trough levels and anti-drug antibodies (ATIs) were also measured. Patients were evaluated 56 weeks (W56) after switch and at week 14 (W14) and week 46 (W46) in the naïve cohort. Conclusion: Switching of IBD patients from original to biosimilar IFX is effective and safe.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30219 - Gastroenterology and hepatology
Návaznosti výsledku
Projekt
—
Návaznosti
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Ostatní
Rok uplatnění
2017
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Digestive Diseases
ISSN
0257-2753
e-ISSN
—
Svazek periodika
35
Číslo periodika v rámci svazku
1-2
Stát vydavatele periodika
CH - Švýcarská konfederace
Počet stran výsledku
10
Strana od-do
91-100
Kód UT WoS článku
000393734900014
EID výsledku v databázi Scopus
2-s2.0-85011715913